CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 233 enrolled
Drug / intervention
Subcutaneous Teriparatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01011556
NCT01011556Phase 2Completed
CompareCT.gov

A Phase 2 Study for Transdermal Application of Teriparatide

Eli Lilly and Company·interventional·Posted Nov 11, 2009·Updated Oct 23, 2012

In Brief

A Phase 2 clinical trial evaluating Subcutaneous Teriparatide and Transdermal Teriparatide for Osteoporosis. Completed, enrolled 233 participants across 18 sites in 5 countries.

Detailed Summary

The primary purpose of this study is to help answer the following research questions: 1. How teriparatide given using a skin patch (transferred through the skin using the ViaDerm Teriparatide System) compares to teriparatide injected under the skin with a needle (pen injector) affects your bone density (how solid or porous your bones are). 2. The safety of the teriparatide skin patch and any side effects that might be associated with it.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesArgentina, Estonia, Hungary, Mexico, Romania
CollaboratorsTransPharma Medical

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 11, 2009
Enrollment StartNov 1, 2009
Primary CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.6 years ago

Interventions

Subcutaneous Teriparatidedrug

Administered subcutaneously once daily for 12 months

Transdermal Teriparatidedrug

Administered transdermally, applied once daily for 6 hours over 12 months